Glaucoma News and Research

Latest Glaucoma News and Research

Director of Scheie Eye Institute honored with WIO's Suzanne Veronneau Troutman Award

Joan M. O'Brien, MD, the George E. de Schweinitz and William F. Norris Professor of Ophthalmology, chair of the Department of Ophthalmology and director of the Scheie Eye Institute at the Perelman School of Medicine at the University of Pennsylvania, was recently presented with the Women in Ophthalmology's Suzanne Veronneau Troutman Award.

26 Nov 2013

Genetic diagnostic test for inherited eye diseases now available from Mass. Eye and Ear

The Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology today announced the availability of a comprehensive genetic diagnostic test for inherited eye diseases.

22 Nov 2013

Research shows oral contraceptive use over three years could be a risk factor for glaucoma

Research presented today, at the 117th Annual Meeting of the American Academy of Ophthalmology in New Orleans, has found that women who have taken oral contraceptives for three or more years are twice as likely to suffer from glaucoma, one of the leading causes of blindness which affects nearly 60 million worldwide. The researchers caution gynecologists and ophthalmologists to be aware of the fact that oral contraceptives might play a role in glaucomatous diseases, and inform patients to have their eyes screened for glaucoma if they also have other risk factors.

19 Nov 2013

ACADIA Pharmaceuticals initiates pimavanserin Phase II trial in ADP patients

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has initiated a Phase II feasibility trial designed to examine the efficacy and safety of pimavanserin as a treatment for patients with Alzheimer's disease psychosis.

15 Nov 2013

Researchers study link between vision loss and Alzheimer's disease

An international team of researchers studying the link between vision loss and Alzheimer's disease report that the loss of a particular layer of retinal cells not previously investigated may reveal the disease's presence and provide a new way to track disease progression.

14 Nov 2013

Sleep Science's new OSA treatment to be presented in WHO Compendium of Innovative Technologies

Sleep Science Partners' mandibular repositioning treatment for obstructive sleep apnea has been accepted for inclusion in the 2013 World Health Organization Compendium of Innovative Technologies to be published this November.

6 Nov 2013

NTU establishes new $60 million research institute in Nanomedicine

Nanyang Technological University is giving the development of nanotechnology a big boost, by establishing a new $60 million research institute in Nanomedicine, which focuses on the medical application of nanotechnology. An emerging field in drugs, nanomedicine are made up of tiny nano-sized particles thousands of times smaller than a grain of sand.

5 Nov 2013

Oligomeric proanthocyanidin has protective effect on retinal ganglion cells, shows study

The death of retinal ganglion cells is a hallmark of many optic neurodegenerative diseases such as glaucoma and retinopathy. Oxidative stress is one of the major reasons to cause the cell death.

4 Nov 2013

Eliza's Star multi-modal programs address gaps in healthcare

Eliza Corporation ("Eliza"), the pioneer and recognized leader in Health Engagement Management, today announced "Star 2014", a proactive member communication solutions suite that addresses key areas of the Centers for Medicare & Medicaid Services (CMS) Star programs.

30 Oct 2013

Once-daily prescription medicine for COPD now available throughout the U.S.

GlaxoSmithKline plc and Theravance, Inc. today announced that BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease, is now available to pharmacies throughout the U.S.

30 Oct 2013

$Adalimumab may be viable treatment option for patients with refractory pediatric uveitis$

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

A new study published in the current issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) suggests that the biologic agent adalimumab may be a viable treatment option for patients with steroid-resistant refractory pediatric uveitis.

22 Oct 2013

pSivida reports that Alimera Sciences gets FDA Complete Response Letter for ILUVIEN NDA

pSivida Corp., a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that its licensee Alimera Sciences, Inc. has received a Complete Response Letter for the New Drug Application for ILUVIEN from the U.S. Food and Drug Administration.

18 Oct 2013

ADAGES III study receives NIH grant to elucidate genetics of glaucoma in African descents

A study led by Robert N. Weinreb, chairman and Distinguished Professor of Ophthalmology at the University of California, San Diego School of Medicine, has received a $6.4 million, 5-year grant from the National Eye Institute, part of the National Institutes of Health, to elucidate the genetics of glaucoma in persons of African descent.

12 Oct 2013

Data analyses from Brisdelle Phase 3 pivotal trials to be showcased at NAMS' meeting

Noven Pharmaceuticals, Inc., today announced that 11 presentations, featuring data analyses from its Phase 3 pivotal trials that supported the recent U.S. Food and Drug Administration approval of Brisdelle (paroxetine capsules, 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms associated with menopause, will be showcased at the 2013 Annual Meeting of The North American Menopause Society in Dallas on Oct. 9-10.

2 Oct 2013

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

...

2 Oct 2013

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

...

1 Oct 2013

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

Sun Pharmaceutical Industries Ltd., an international specialty pharmaceutical company focused on chronic diseases, through its subsidiary, and Intrexon Corporation, a leader in synthetic biology, today announced the formation of a joint venture to develop controllable gene-based therapies for the treatment of ocular diseases that cause partial or total blindness in millions of people worldwide.

1 Oct 2013

Optic flow enables perception despite blur image

Blurred images that are unidentifiable as still pictures become understandable once the images are set in motion. That's because of a phenomenon called "optic flow"—which may be especially relevant as a source of visual information in people with low vision, reports a study 'With an Eye to Low Vision: Optic Flow Enables Perception Despite Image Blur' in the October issue of Optometry and Vision Science official journal of the American Academy of Optometry.

27 Sep 2013

IRIDEX's MicroPulse Laser Therapy to be featured at EURETINA and ESCRS conferences

IRIDEX today announced a number of key international conferences and workshops that will feature its proprietary MicroPulse Laser Therapy for the treatment of diabetes and glaucoma related disorders.

26 Sep 2013

New laser provides better treatment for eye diseases in diabetes patients

A new laser is helping experts at the Truhlsen Eye Institute at the University of Nebraska Medical Center provide better treatment for eye diseases. This advanced laser can prevent blindness for some patients with serious conditions.

24 Sep 2013

Glaucoma News and Research

Latest Glaucoma News and Research

Director of Scheie Eye Institute honored with WIO's Suzanne Veronneau Troutman Award

Genetic diagnostic test for inherited eye diseases now available from Mass. Eye and Ear

Research shows oral contraceptive use over three years could be a risk factor for glaucoma

ACADIA Pharmaceuticals initiates pimavanserin Phase II trial in ADP patients

Researchers study link between vision loss and Alzheimer's disease

Sleep Science's new OSA treatment to be presented in WHO Compendium of Innovative Technologies

NTU establishes new $60 million research institute in Nanomedicine

Oligomeric proanthocyanidin has protective effect on retinal ganglion cells, shows study

Eliza's Star multi-modal programs address gaps in healthcare

Once-daily prescription medicine for COPD now available throughout the U.S.

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

pSivida reports that Alimera Sciences gets FDA Complete Response Letter for ILUVIEN NDA

ADAGES III study receives NIH grant to elucidate genetics of glaucoma in African descents

Data analyses from Brisdelle Phase 3 pivotal trials to be showcased at NAMS' meeting

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

Optic flow enables perception despite blur image

IRIDEX's MicroPulse Laser Therapy to be featured at EURETINA and ESCRS conferences

New laser provides better treatment for eye diseases in diabetes patients

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Glaucoma News and Research

Latest Glaucoma News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in